SABCS 2025: Latest developments in multigene testing in early breast cancer

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years